[go: up one dir, main page]

IL129616A0 - Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes - Google Patents

Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Info

Publication number
IL129616A0
IL129616A0 IL12961697A IL12961697A IL129616A0 IL 129616 A0 IL129616 A0 IL 129616A0 IL 12961697 A IL12961697 A IL 12961697A IL 12961697 A IL12961697 A IL 12961697A IL 129616 A0 IL129616 A0 IL 129616A0
Authority
IL
Israel
Prior art keywords
syndromes
prevention
treatment
related diseases
derivatives useful
Prior art date
Application number
IL12961697A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL129616A0 publication Critical patent/IL129616A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
IL12961697A 1996-10-28 1997-10-28 Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes IL129616A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK119796 1996-10-28
PCT/DK1997/000483 WO1998018776A1 (en) 1996-10-28 1997-10-28 Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Publications (1)

Publication Number Publication Date
IL129616A0 true IL129616A0 (en) 2000-02-29

Family

ID=8102066

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12961697A IL129616A0 (en) 1996-10-28 1997-10-28 Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Country Status (12)

Country Link
EP (1) EP0937060B1 (no)
JP (1) JP2001502708A (no)
AT (1) ATE229518T1 (no)
AU (1) AU4772097A (no)
CA (1) CA2269974A1 (no)
DE (1) DE69717843T2 (no)
DK (1) DK0937060T3 (no)
ES (1) ES2188908T3 (no)
IL (1) IL129616A0 (no)
NO (1) NO992003L (no)
WO (1) WO1998018776A1 (no)
ZA (1) ZA979647B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69716292T2 (de) * 1996-12-13 2003-07-03 Chugai Seiyaku K.K., Tokio/Tokyo Benzopyranderivate
CA2356986A1 (en) * 1998-12-30 2000-07-06 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2001042234A1 (en) * 1999-12-13 2001-06-14 Chugai Seiyaku Kabushiki Kaisha 3-methyl-chroman and -thiochroman derivatives
KR20010055766A (ko) * 1999-12-13 2001-07-04 이경하 3-메틸-크로만 또는 티오크로만 유도체의 금속염
KR20010055765A (ko) * 1999-12-13 2001-07-04 이경하 3-메틸-크로만 또는 티오크로만 유도체
JP4913056B2 (ja) * 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP1794141B1 (en) 2004-09-21 2011-11-09 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
MX2012014431A (es) 2010-06-10 2013-02-26 Aragon Pharmaceuticals Inc Modulares del receptor de estrogenos y usos de los mismos.
US9708283B2 (en) 2010-11-01 2017-07-18 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
JP2015500346A (ja) 2011-12-14 2015-01-05 セラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその使用
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders

Also Published As

Publication number Publication date
CA2269974A1 (en) 1998-05-07
EP0937060A1 (en) 1999-08-25
DK0937060T3 (da) 2003-04-07
WO1998018776A1 (en) 1998-05-07
NO992003D0 (no) 1999-04-27
ES2188908T3 (es) 2003-07-01
AU4772097A (en) 1998-05-22
DE69717843T2 (de) 2003-09-25
ATE229518T1 (de) 2002-12-15
NO992003L (no) 1999-06-25
ZA979647B (en) 1998-04-28
DE69717843D1 (de) 2003-01-23
EP0937060B1 (en) 2002-12-11
JP2001502708A (ja) 2001-02-27

Similar Documents

Publication Publication Date Title
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
HUT70526A (en) Indole-2-carboxylic acid derivatives, process for producing thereof and pharmaceutical compositions comprising same compounds
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
HUP9901616A3 (en) Novel benzofuranone derivatives, process for their production and pharmaceutical compositions of the same
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
UA35607C2 (uk) Похідні оксазолідинонкарбонової кислоти, спосіб їх одержання, фармацевтична композиція і спосіб її одержання
AU1306795A (en) Anticonvulsant pseudofructopyranose sulfamates
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
IL129627A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129625A0 (en) Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU5493298A (en) Stabilized pharmaceutical compositions and process for the preparation thereof
CA2263846A1 (en) Novel pyranoside derivatives
NO992010L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
MY115795A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
NO992005L (no) Nye cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
NO992008L (no) Nye (+)-enantiomerer av cis-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives